Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial

2014 ◽  
Vol 17 (2) ◽  
pp. 371-373 ◽  
Author(s):  
M. Fujimura ◽  
H. Ishimaru ◽  
Y. Nakatsuji
Keyword(s):  
Atopic Dermatitis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Crossover Trial ◽  
Severity Index ◽  
Base Line ◽  
Double Blind ◽  
Canine Atopic Dermatitis ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Ssri Treatment

Abstract This study investigated effects of a fluoxetine (selective serotonin reuptake inhibitors; SSRI, 1 mg/kg) on pruritus in canine atopic dermatitis (CAD). After 4-weeks of base-line observation, 8 dogs with CAD entered a 2-months randomized, double-blind, placebo-controlled, crossover trial comparing fluoxetine with placebo. Clinical efficacy was evaluated using a Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and Pruritus Visual Analog Scale (PVAS). Six dogs completed the study [two out of eight dogs (both of them were Shiba Inu) dropped out from the study due to a depression]. CADESI-03 and PVAS between fluoxetine and placebo showed no significant difference statistically (P>0.05 and P>0.05 respectively). Fluoxetine showed no efficacy on pruritus in CAD. Further researches are needed for the treatment on pruritus of CAD

Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial

2002 ◽  
Vol 147 (2) ◽  
pp. 324-330 ◽  
Author(s):  
J. Berth-Jones ◽  
A. Takwale ◽  
E. Tan ◽  
G. Barclay ◽  
S. Agarwal ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Crossover Trial ◽  
Double Blind ◽  
Double Blind Placebo

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial

2011 ◽  
Vol 22 (6) ◽  
pp. 554-564 ◽  
Author(s):  
Pierre Cadot ◽  
Patrick Hensel ◽  
Emmanuel Bensignor ◽  
Céline Hadjaje ◽  
Geneviève Marignac ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Phase 3 ◽  
Double Blind ◽  
Canine Atopic Dermatitis ◽  
Double Blind Placebo

The Influence of Topical Unsaturated Fatty Acids and Essential Oils on Normal and Atopic Dogs

2011 ◽  
Vol 47 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Sandra Tretter ◽  
Ralf S. Mueller
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Essential Oils ◽  
Unsaturated Fatty Acids ◽  
Severity Index ◽  
Transepidermal Water Loss ◽  
Closed Chamber ◽  
Canine Atopic Dermatitis ◽  
Significant Difference ◽  
Before And After

Seven dogs with atopic dermatitis and six normal dogs were treated with a spot-on product containing essential oils and unsaturated fatty acids q 7 days for 8 wk. Seven additional atopic dogs received a daily spray containing similar ingredients to the spot-on. In all dogs, transepidermal water loss (TEWL) was measured before and after treatment using a closed chamber device. In atopic dogs, a validated lesion score (canine atopic dermatitis extent and severity index, CADESI) was determined and pruritus was assessed with a visual analog scale before and after treatment. The mean CADESI scores in atopic dogs decreased with the spot-on (P=0.0043) and with the spray (P=0.0366). Similarly, the pruritus scores decreased with the spot-on (P=0.266) and with the spray (P=0.0177). There was a significant difference between the TEWL values of healthy and atopic dogs on the abdomen (P=0.0181) and back (P=0.0123). TEWL decreased significantly on the back after treatment with the spray (P=0.016), but not on the abdomen (P=0.078). Adverse effects were not observed. The results of this pilot study indicate that topical fatty acids and essential oils are a useful treatment option for canine atopic dermatitis.

scholarly journals RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF FOLIC ACID ADJUNCT FOR 8 WEEKS IN HYPERHOMOCYSTEINAEMIC HYPERTENSIVE PATIENTS IN ZARIA, NIGERIA

2018 ◽  
Vol 8 (5) ◽  
pp. 338-348 ◽  
Author(s):  
Obiageli U ONYEMELUKWE ◽  
Bilkisu B MAIHA ◽  
Lydia O AYANWUYI ◽  
Tukur DAHIRU
Keyword(s):  
Blood Pressure ◽  
Folic Acid ◽  
Repeated Measures ◽  
Controlled Study ◽  
Base Line ◽  
Double Blind ◽  
Adjunct Therapy ◽  
Hypertensive Patients ◽  
Double Blind Placebo ◽  
Significant Difference

Objectives: This study was aimed at determining the effect of folic acid adjunct therapy on homocysteine (HCY) and blood pressure (BP) levels in hypertensive subjects. Method: The study was a double blind placebo-controlled trial on 100 hypertensive patients randomised into 50 folate and 50 placebo groups, where the folate group had 5 mg folic acid daily for 8 weeks. Fasting plasma homocysteine, folate and blood pressure levels were determined at baseline, at 4 and at 8 weeks. The Mixed Model Repeated Measures analysis of variance was applied for data analysis. Results: Hyperhomocysteinaemia was found at baseline in the folate (21.3 ± 5.7 µmol/L) and placebo (21.6 ± 4.9 µmol/L) groups which did not differ statistically (p > 0.05). Folic acid adjunct therapy, reduced homocysteine levels at 4 weeks by 2.0 µmol/L (9.2 %, p < 0.05) and at 8 weeks by 1.2 µmol/L (5.6 %, p < 0.05), with no significant (p > 0.05) systolic and diastolic blood pressure lowering effect. High base-line folate levels were found in both folate (113.8 ± 51.2 ng/ml) and placebo groups (109.5 ± 51.4 ng/ml) with no statistically significant difference (p > 0.05). Conclusion: Short-term daily folic acid supplementation over 8 weeks had a significant homocysteine reduction effect with no significant reduction in systolic and diastolic blood pressures of hypertensive subjects in Zaria, Nigeria. Hyperhomocysteinaemia could not be accounted for by suboptimal folate levels. Keywords: Hypertension, Homocysteine, Blood pressure, Folate, Placebo, Nigeria.

Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study

Cephalalgia ◽  
1988 ◽  
Vol 8 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Fulvio Sorge ◽  
Roberto De Simone ◽  
Enrico Marano ◽  
Maria Nolano ◽  
Giuseppe Orefice ◽  
...  
Keyword(s):  
Side Effects ◽  
Crossover Trial ◽  
Average Duration ◽  
Base Line ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Childhood Migraine ◽  
Group A ◽  
Group B ◽  
Line Observation

An 8-month, double-blind, placebo-controlled, crossover trial of flunarizine in the prophylaxis of migraine has been performed in 70 children. After 4 weeks of medication-free base-line observation, 35 children (group A) received flunarizine (5 mg/day) and 35 (group B) received placebo over a 12-week period. After a 4-week washout they crossed treatments for another 12 weeks. Sixty-three patients completed the trial. In both groups flunarizine significantly reduced the frequency and average duration of headache attacks. In group A efficacy was maintained after placebo crossover for the last 4 months of the study. Five subjects in group B stopped placebo because of ineffectiveness; two children in group A discontinued flunarizine treatment, one because of excessive daytime sedation and the other because therapy was ineffective. The main side effects were daytime sedation and weight gain. It is concluded that flunarizine is an effective drug for the treatment of childhood migraine. In a study of this length no serious side effects were discovered.

Sign in / Sign up

Export Citation Format

Share Document